Alantra advises Pharm-Rx on the sale of the company to Actylis

Oct 2024

Sell-side advisory

Boston – Alantra has acted as financial advisor to Pharm-Rx, a leading value-added supplier of specialty ingredients for the vitamin, mineral, and supplement (“VMS”) and pharmaceutical industries, on its sale to Actylis, a leading provider of life sciences and advanced technology specialty ingredients.

For more than 30 years, Pharm-Rx has been a leading supplier of active ingredients to the VMS, over-the-counter (“OTC”), and prescription pharmaceutical markets. It is well known for its customer-centric approach, identifying difficult-to-find specialty ingredients from premier manufacturers globally. Pharm-Rx has developed industry-leading expertise in addressing customer needs, overcoming regulatory hurdles, and navigating international logistics complexities.

Actylis, owned by New Mountain Capital, is a provider of choice for differentiated specialty ingredients in the life sciences and advanced technology end markets. With business operations in 10 countries, Actylis manufactures and supplies more than 3,000 chemical compounds used principally by the pharmaceutical, nutraceutical, agricultural, and specialty chemical industries. 

The Pharm-Rx acquisition significantly enhances Actylis’ ability to deliver exceptional value to its customers and strengthens its strategic supplier partnerships to enhance its innovative portfolio and service offerings. Actylis can now provide an even more comprehensive range of solutions to meet the evolving needs of customers. Furthermore, the integration of Pharm-Rx’s strong team and industry expertise broadens Actylis’ capabilities to help accelerate the growth of its nutrition and OTC customers.

Joshua Garver, Managing Director at Alantra, said: “We are pleased to have played a role in facilitating the combination of Pharm-Rx and Actylis, in which our team’s deep expertise in the VMS and Consumer Healthcare sectors helped lead to this partnership. We are confident that the addition of Pharm-Rx to Actylis will enable the company to continue its strong growth trajectory and deliver even greater value to its customers.”

This transaction further reinforces Alantra’s continued momentum in the VMS and Consumer Healthcare industries, where the team has recently advised on a variety of deals such as the sale of UST to Somafina, backed by Heartwood Partners, the sale of medneo Group’s UK diagnostic imaging business to CVC DIF, and the sale of vH essentials®, formerly owned by Wisconsin Pharmacal, to Avista-backed Wellspring Consumer Healthcare.